KR102622245B1 - 근육 성능 개선 화합물 - Google Patents

근육 성능 개선 화합물 Download PDF

Info

Publication number
KR102622245B1
KR102622245B1 KR1020197018624A KR20197018624A KR102622245B1 KR 102622245 B1 KR102622245 B1 KR 102622245B1 KR 1020197018624 A KR1020197018624 A KR 1020197018624A KR 20197018624 A KR20197018624 A KR 20197018624A KR 102622245 B1 KR102622245 B1 KR 102622245B1
Authority
KR
South Korea
Prior art keywords
leu
val
ser
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197018624A
Other languages
English (en)
Korean (ko)
Other versions
KR20190085132A (ko
Inventor
얀 빌렘 브리플뢰트
마리나 마리아 보이도
올레나 부텐코
로베르타 셸리노
Original Assignee
파르마폭스 테라퓨틱스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르마폭스 테라퓨틱스 아게 filed Critical 파르마폭스 테라퓨틱스 아게
Publication of KR20190085132A publication Critical patent/KR20190085132A/ko
Application granted granted Critical
Publication of KR102622245B1 publication Critical patent/KR102622245B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197018624A 2016-11-29 2017-11-28 근육 성능 개선 화합물 Active KR102622245B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1620119.6 2016-11-29
GBGB1620119.6A GB201620119D0 (en) 2016-11-29 2016-11-29 Compounds
PCT/IB2017/057436 WO2018100483A1 (en) 2016-11-29 2017-11-28 Muscle performance improvement compounds

Publications (2)

Publication Number Publication Date
KR20190085132A KR20190085132A (ko) 2019-07-17
KR102622245B1 true KR102622245B1 (ko) 2024-01-05

Family

ID=58073474

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018624A Active KR102622245B1 (ko) 2016-11-29 2017-11-28 근육 성능 개선 화합물

Country Status (11)

Country Link
US (1) US11407799B2 (https=)
EP (1) EP3548509A1 (https=)
JP (2) JP7683901B2 (https=)
KR (1) KR102622245B1 (https=)
CN (1) CN110036024B (https=)
AU (1) AU2017367277B2 (https=)
CA (1) CA3045245A1 (https=)
GB (1) GB201620119D0 (https=)
NZ (1) NZ754625A (https=)
WO (1) WO2018100483A1 (https=)
ZA (1) ZA201903261B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110430890B (zh) 2016-11-10 2024-09-10 科乐斯疗法公司 激活素受体iia型变体及其使用方法
EP3706777B1 (en) 2017-11-09 2024-05-22 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
JP7405772B2 (ja) 2018-05-09 2023-12-26 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物
JP2023512423A (ja) * 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them
CN116171147A (zh) * 2020-07-24 2023-05-26 新加坡科技研究局 伤口愈合组合物及其用途
JP2024511315A (ja) * 2021-03-10 2024-03-13 アクセルロン ファーマ インコーポレイテッド Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法
US20250064952A1 (en) * 2021-03-10 2025-02-27 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
KR20240029031A (ko) 2021-06-21 2024-03-05 쥬베나 테라퓨틱스, 인크. 재생 폴리펩티드 및 이의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516886A (ja) 2002-10-25 2006-07-13 ワイエス Ａｃｔｒｉｉｂ融合ポリペプチドおよびその使用
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
JP2010502633A (ja) 2006-09-05 2010-01-28 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
US20110135638A1 (en) 2009-11-17 2011-06-09 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2012525128A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
JP2013503825A (ja) * 2009-09-04 2013-02-04 ニューロチューン・アクチエンゲゼルシャフト 薬物として用いる、筋力を回復する能力がある改変アグリン断片

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434934D1 (de) * 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
US20100004171A1 (en) 2006-08-08 2010-01-07 Bazan Nicolas G Therapeutic Methods for Neuropathic Pain
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516886A (ja) 2002-10-25 2006-07-13 ワイエス Ａｃｔｒｉｉｂ融合ポリペプチドおよびその使用
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
JP2010502633A (ja) 2006-09-05 2010-01-28 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
JP2012525128A (ja) 2009-04-27 2012-10-22 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
JP2013503825A (ja) * 2009-09-04 2013-02-04 ニューロチューン・アクチエンゲゼルシャフト 薬物として用いる、筋力を回復する能力がある改変アグリン断片
US20110135638A1 (en) 2009-11-17 2011-06-09 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2013511474A (ja) * 2009-11-17 2013-04-04 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Experimental Gerontology 85(8962):1-8(2016.09.12.)
Nature Reviews Drug Discovery 14(1):58-74(2014.12.31.)

Also Published As

Publication number Publication date
WO2018100483A1 (en) 2018-06-07
JP2019536818A (ja) 2019-12-19
AU2017367277B2 (en) 2021-04-01
JP2023116479A (ja) 2023-08-22
NZ754625A (en) 2023-03-31
EP3548509A1 (en) 2019-10-09
CN110036024A (zh) 2019-07-19
CN110036024B (zh) 2024-05-07
JP7683901B2 (ja) 2025-05-27
GB201620119D0 (en) 2017-01-11
CA3045245A1 (en) 2018-06-07
ZA201903261B (en) 2020-02-26
KR20190085132A (ko) 2019-07-17
US20210253654A1 (en) 2021-08-19
AU2017367277A1 (en) 2019-07-04
US11407799B2 (en) 2022-08-09

Similar Documents

Publication Publication Date Title
KR102622245B1 (ko) 근육 성능 개선 화합물
JP7427046B2 (ja) Ｂｄｎｆを含む融合蛋白質
JP4790624B2 (ja) 生体分子パーティションモチーフ及びそれらの使用
JP4222629B2 (ja) ニュールツリンおよび関連成長因子
JP2021527656A (ja) プログラニュリンを含む融合タンパク質
CA3049023A1 (en) Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
SK4512002A3 (en) April-r antagonist for the treatment of diseases related to undesirable cell proliferation
US12384822B2 (en) TAM receptor-binding fusion molecule having non-inflammatory phagocytosis inducing activity
JP2020524661A (ja) 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ−１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
JP2014502965A (ja) ｕＰＡＲアンタゴニストおよびその使用
JP2017513921A (ja) ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質
JP2026053559A (ja) ヘテロ二量体リラキシン融合物及びその使用
AU2002332732A1 (en) Bv8 nucleic acids and polypeptides with mitogenic activity
EP1427830A2 (en) Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
ES2259458T3 (es) Persefina humana.
CN101627053A (zh) 泛细胞表面受体特异的治疗剂
WO2016143702A1 (ja) 抗ヒト膜型ａｄａｍ２８抗体
RU2846293C1 (ru) АНТИТЕЛО К EphA4
KR20180120738A (ko) 톨-유사 수용체 4에 대한 길항제로서의 뉴몰리신 펩타이드의 용도 및 톨-유사 수용체 4 관련 질병을 치료하는 방법
KR20230123923A (ko) 항-EphA4 항체
HK40120919A (zh) 激活素受体iia型变体及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190627

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201127

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230228

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231207

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240103

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240103

End annual number: 3

Start annual number: 1

PG1601 Publication of registration